The blockbuster cancer drug Keytruda can cost over $150,000

This episode of USA Today's The Excerpt explores the staggering cost of Keytruda, a groundbreaking cancer immunotherapy drug produced by Merck, which can exceed $162,000 for a single 400-milligram dose. The story centers on Patricia Brown, a lung cancer patient whose treatment highlighted how U.S. healthcare pricing can escalate through the supply chain, despite her personal out-of-pocket cost being relatively low. Reporter Ken Oldtucker details how the U.S. pharmaceutical system—driven by patent protections, lack of price regulation, and a fragmented supply chain—allows drugmakers to set high list prices, especially compared to other nations. While Keytruda’s development reflects significant medical innovation, the episode raises critical questions about whether the current pricing model is sustainable, especially when lower doses may be equally effective. The discussion also touches on broader systemic issues, including the end of pandemic-era ACA subsidies, ongoing political debates over Medicaid, and the potential for greater pricing transparency and Medicare negotiation to reduce costs. The episode underscores that while innovation in medicine is vital, the U.S. healthcare system’s structure often prioritizes profit over affordability. Experts suggest reforms like increased transparency, stronger negotiation power for Medicare, and reevaluating drug dosing standards could help curb runaway costs. Ultimately, the takeaway is that while breakthroughs like Keytruda offer hope, their accessibility is deeply compromised by a system that lacks price controls and equitable distribution. The conversation calls for systemic change to ensure life-saving treatments are not reserved for the wealthy.